Physician profile
Lin Chen
NPI 1457921140
$6,013.77
in general payments reported to CMS, 2019-2025
48 companies · $1,758 in 2025
The $1,758 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $257 · 2022: $1,278 · 2023: $823 · 2024: $1,898 · 2025: $1,758.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,263 · Education: $216.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,262.85 |
| Education | $215.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $785.27 | 2022-2025 | Imfinzi, Calquence, Lynparza |
| Novartis Pharmaceuticals Corporation | $457.84 | 2022-2025 | |
| Janssen Biotech, INC. | $383.98 | 2021-2025 | Rybrevant, Talvey, Carvykti |
| Incyte Corporation | $372.55 | 2021-2025 | Jakafi, Niktimvo, Monjuvi |
| Merck Sharp & Dohme LLC | $317.99 | 2021-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Glaxosmithkline, LLC. | $295.53 | 2023-2025 | Jemperli, Zejula |
| Takeda Pharmaceuticals U.S.A., INC. | $279.84 | 2022-2025 | Ninlaro, Vpriv, Alunbrig |
| Gilead Sciences, INC. | $230.11 | 2024-2025 | Trodelvy |
| Pfizer INC. | $217.27 | 2021-2025 | |
| Seagen INC. | $208.25 | 2021-2023 | Tukysa, Tivdak |
| Celgene Corporation | $172.82 | 2022-2025 | Reblozyl, Pomalyst |
| E.R. Squibb & Sons, L.L.C. | $154.44 | 2022-2025 | Opdivo |
| Abbvie INC. | $154.04 | 2022-2025 | |
| Aveo Pharmaceuticals, INC. | $149.87 | 2021-2025 | |
| Daiichi Sankyo INC. | $122.09 | 2022-2025 | Datroway, Enhertu, Injectafer |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lin Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.